Watercress will be tested in its natural form as a food item that will supplement the usual diet, via the prescription of watercress as whole food added daily to the usual diet. The intervention group will be asked to consume 100 grams of watercress per day, in addition to their usual diet for the total time of RT treatment. These 100 grams of watercress per day will allow the achievement of the daily "therapeutic" dose.

The control group will receive the standard of care, thus will maintain their ad libitum diet.

Long-term Effects Secondary to Cancer Therapy in Adults

100g of watercress daily during radiation therapy

Watercress

Hospital de Santa Maria

Does Watercress Intake Have an Impact on Cancer Patients Outcomes: a Longitudinal Trial

Does Watercress Intake Have an Impact on Cancer Patients Outcomes: a Randomized Longitudinal Trial

as an indirect measure of cell membrane integrity, function and metabolism

assessed by tetrapolar multifrequency Bioimpedance Analysis (BIA) and CT scan images; CT scans analysis will be performed in collaboration with expert groups

Assessed by the RTOG Common Toxicity Criteria, developed by the Eastern Cooperative Oncology Group (RTOG)

Evaluated by a radiation oncologist, using a validated toxicity scale

will be assessed by the European Organisation for Research and Treatment of Cancer (EORTC-QLQ C30), validated for Oncology

DNA damage assessment by Comet assay in lymphocytes has been used extensively as a surrogate biomarker to measure exposure to genotoxic agents and assess cancer risk in human studies by us and others. biological samples will comprise serum or plasma (1 mL) prepared from blood samples collected in Heparin tubes and urine (1 mL). Metabolomic profiles will be measured on a 700 MHz 1H NMR spectrometer equipped with a cryo-probe for enhanced sensitivity. 1H NMR spectroscopy: high throughput metabolic phenotyping is a powerful approach for characterising biochemical signatures of biological samples. We will couple high-resolution 1H NMR spectroscopy and mathematical modelling approaches to determine the metabolic profile in biological samples from patients.

Metabolomics simultaneously measures thousands of low molecular weight metabolites providing holistic information on the biochemical status of the body. Previous metabolomic studies have identified cancer-associated perturbations in the metabolic phenotypes of patients. This study will explore the ability of watercress to improve the restorative effects of radiotherapy in breast cancer patients on the metabolic status towards a healthy phenotype

assessed by the method Patient-Generated Subjective Global Assessment, specific and validated for Oncology

Will derive from a diet history and a 24-hour-recall food questionnaire. The software Dietplan6 (Forestfield Software Ltd 2013®, Horsham, UK) will analyze the nutrient content of foods consumed

The plasma samples analysis will also include the measurement of carotenoids and flavonoids, which are present in watercress, and are related with antigenotoxic effects in vitro and have anti-proliferative effects, as demonstrated in several studies. Urine samples analysis will allow the measurement of flavonoids.

assessed by tetrapolar multifrequency Bioimpedance Analysis (BIA)

Paula Ravasco

Principal Investigator

University of Lisbon

Epirubicin 90 mg/m2 and cyclophosphamide 600mg/m2 IV every 3 weeks for 4 cycles.
Nab paclitaxel 125mg/m2 IV days 1, 8 and 15 for 12 weeks In case of HER2 positive tumour patients will receive trastuzumab in combination with nab-Paclitaxel

Breast Cancer

Nab-Paclitaxel- 125 mg/m2 days 1,8, 15 for 12 weeks

Nab-Paclitaxel

Bankstown Lidcome Hospital

Royal North Shore Hospital

Barwon Health

St John of God Healthcare, Geelong

South West Healthcare

IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer

Tailored Neoadjuvant Epirubicin and Cyclophosphamide (EC) and Nanoparticle Albumin Bound (Nab) Paclitaxel for Newly Diagnosed Breast Cancer

Pathological complete response defined as breast only, ypT0/ ypTis regardless of nodal status

Safety will be measured using NCI Common Toxicity Criteria for Adverse Effects version 4.0

Patients receive broccoli sprout extract PO QD on days 1-14 immediately prior to surgery.

Patients receive placebo PO QD on days 1-14 immediately prior to surgery.

Ductal Breast Carcinoma

Ductal Breast Carcinoma In Situ

Estrogen Receptor Negative

Estrogen Receptor Positive

Invasive Breast Carcinoma

Lobular Breast Carcinoma

Postmenopausal

Stage IA Breast Cancer

Stage IB Breast Cancer

Stage IIA Breast Cancer

Stage IIB Breast Cancer

Broccoli Sprout Extract

Laboratory Biomarker Analysis

Pharmacological Study

Placebo

Roswell Park Cancer Institute

Broccoli Sprout Extract in Treating Patients With Breast Cancer

A Pilot Study of Broccoli Sprout Extract in Patients With Breast Cancer

Appropriate transformation (such log transformation) will be used to achieve normality of the data. Results will be given as the back-transformed geometric means and 95% confidence intervals in order to preserve the units of measurement. Change in immunohistochemistry measures will be calculated for each individual and compared between treatment and placebo groups by use of independent samples t-test. If the normality could not be reached by transformation, Wilcoxon rank-sum test will be used, which considers both the direction and the magnitude of changes.

quinone/rak dojke

Does Watercress Intake Have an Impact on Cancer Patients Outcomes: a Longitudinal Trial

IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer

Broccoli Sprout Extract in Treating Patients With Breast Cancer

SWOG 8897-A DNA Analysis in Predicting Treatment Outcome in Women With Breast Cancer in SWOG 8897

Najkompletnija baza ljekovitog bilja potpomognuta znanošću